General Services Administration Acquisition Regulation; Information Collection; Zero Burden Information Collection Reports, 58308-58309 [E7-20255]
Download as PDF
58308
Federal Register / Vol. 72, No. 198 / Monday, October 15, 2007 / Notices
sroberts on PROD1PC70 with NOTICES
Analysis to Aid Public Comment
describes the terms of the consent
agreement, and the allegations in the
complaint. An electronic copy of the
full text of the consent agreement
package can be obtained from the FTC
Home Page (for October 5, 2007), on the
World Wide Web, at https://www.ftc.gov/
os/2007/10/index.htm. A paper copy
can be obtained from the FTC Public
Reference Room, Room 130-H, 600
Pennsylvania Avenue, N.W.,
Washington, D.C. 20580, either in
person or by calling (202) 326-2222.
Public comments are invited, and may
be filed with the Commission in either
paper or electronic form. All comments
should be filed as prescribed in the
ADDRESSES section above, and must be
received on or before the date specified
in the DATES section.
Analysis of Agreement Containing
Consent Order to Aid Public Comment
The Federal Trade Commission
(‘‘FTC’’ or ‘‘Commission’’) has accepted,
subject to final approval, an agreement
containing a consent order from Merilou
Barnekow, an individual trading and
doing business as Women’s Menopause
Health Center (‘‘respondent’’).
The proposed consent order has been
placed on the public record for thirty
(30) days for reception of comments by
interested persons. Comments received
during this period will become part of
the public record. After thirty (30) days,
the Commission will again review the
agreement and the comments received
and will decide whether it should
withdraw from the agreement or make
final the agreement’s proposed order.
This matter involves the advertising
and promotion of Preserve Progesterone
Cream and Return to Eden Progesterone
Cream, transdermal creams that,
according to their labels, contain, among
other ingredients, natural progesterone.
According to the FTC complaint,
respondent represented that Preserve
Progesterone Cream and Return to Eden
Progesterone Cream: (1) are effective in
preventing, treating, or curing
osteoporosis; (2) are effective in
preventing or reducing the risk of
estrogen-inducted endometrial (uterine)
cancer; and (3) do not increase the
user’s risk of developing breast cancer
and/or are effective in preventing or
reducing the user’s risk of developing
breast cancer. The complaint alleges
that respondent failed to have
substantiation for these claims. The
proposed consent order contains
provisions designed to prevent
respondent from engaging in similar
acts and practices in the future.
Part I of the proposed order requires
respondents to have competent and
VerDate Aug<31>2005
21:55 Oct 12, 2007
Jkt 214001
reliable scientific evidence
substantiating claims that any
progesterone product or any other
dietary supplement, food, drug, device
or health-related service or program is
effective in preventing, treating, or
curing osteoporosis, in preventing or
reducing the risk of estrogen-induced
endometrial cancer or breast cancer, or
in the mitigation, treatment, prevention,
or cure of any disease, illness, or health
condition; that it does not increase the
user’s risk of developing breast cancer,
is safe for human use, or has no side
effects; or about its health benefits,
performance, efficacy, safety, or side
effects.
Part II of the proposed order prevents
respondent from misrepresenting the
existence, contents, validity, results,
conclusions, or interpretations of any
test, study, or research.
Part III of the proposed order provides
that the order does not prohibit
respondent from making representations
for any drug that are permitted in
labeling for the drug under any tentative
final or final Food and Drug
Administration (‘‘FDA’’) standard or
under any new drug application
approved by the FDA; representations
for any medical device that are
permitted in labeling under any new
medical device application approved by
the FDA; and representations for any
product that are specifically permitted
in labeling for that product by
regulations issued by the FDA under the
Nutrition Labeling and Education Act of
1990.
Parts IV through VIII require
respondent to keep copies of relevant
advertisements and materials
substantiating claims made in the
advertisements; to provide copies of the
order to certain of her personnel; to
notify the Commission of changes in
corporate structure and changes in
employment that might affect
compliance obligations under the order;
and to file compliance reports with the
Commission. Part IX provides that the
order will terminate after twenty (20)
years under certain circumstances.
The purpose of this analysis is to
facilitate public comment on the
proposed order. It is not intended to
constitute an official interpretation of
the agreement and proposed order or to
modify in any way their terms.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. E7–20271 Filed 10–12–07: 8:45 am]
[BILLING CODE 6750–01–S]
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
GENERAL SERVICES
ADMINISTRATION
[OMB Control No. 3090–0250]
General Services Administration
Acquisition Regulation; Information
Collection; Zero Burden Information
Collection Reports
Office of the Chief Acquisition
Officer, GSA.
ACTION: Notice of request for comments
regarding a renewal to an existing OMB
clearance.
AGENCY:
SUMMARY: Under the provisions of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35), the General Services
Administration will be submitting to the
Office of Management and Budget
(OMB) a request to review and approve
an extension of a currently approved
information collection requirement
regarding zero burden information
collection reports. The clearance
currently expires on August 31, 2007.
Public comments are particularly
invited on: Whether this collection of
information is necessary and whether it
will have practical utility; whether our
estimate of the public burden of this
collection of information is accurate and
based on valid assumptions and
methodology; and ways to enhance the
quality, utility, and clarity of the
information to be collected.
DATES: Submit comments on or before:
December 14, 2007.
FOR FURTHER INFORMATION CONTACT:
William Clark, Procurement Analyst,
Contract Policy Division, at telephone
(202) 219–1813 or via e-mail to
william.clark @gsa.gov.
ADDRESSES: Submit comments regarding
this burden estimate or any other aspect
of this collection of information,
including suggestions for reducing this
burden to the Regulatory Secretariat
(VIR), General Services Administration,
Room 4035, 1800 F Street, NW.,
Washington, DC 20405. Please cite OMB
Control No. 3090–0250, Zero Burden
Information Collection Reports, in all
correspondence.
SUPPLEMENTARY INFORMATION:
A. Purpose
This information requirement consists
of reports that do not impose collection
burdens upon the public. These
collections require information which is
already available to the public at large
or that is routinely exchanged by firms
during the normal course of business. A
general control number for these
collections decreases the amount of
paperwork generated by the approval
process.
E:\FR\FM\15OCN1.SGM
15OCN1
Federal Register / Vol. 72, No. 198 / Monday, October 15, 2007 / Notices
GSA has published rules in the
Federal Register that fall under
information collection 3090–0250. The
rule that prescribed clause 552.238–70
‘‘Identification of Electronic Office
Equipment Providing Accessibility for
the Handicapped’’ was published at 56
FR 29442, June 27, 1991, titled
‘‘Implementation of Public Law 99–
506’’, with an effective date of July 8,
1991; and Clause 552.238–74
‘‘Industrial Funding Fee and Sales
Reporting’’ published at 68 FR 41286,
July 11, 2003.
B. Annual Reporting Burden
None.
OBTAINING COPIES OF
PROPOSALS: Requesters may obtain a
copy of the information collection
documents from the General Services
Administration, Regulatory Secretariat
(VIR), 1800 F Street, NW., Room 4035,
Washington, DC 20405, telephone (202)
501–4755. Please cite OMB Control No.
3090–0250, Zero Burden Information
Collection Reports, in all
correspondence.
Dated: October 5, 2007.
Al Matera,
Director, Office of Acquisition Policy.
[FR Doc. E7–20255 Filed 10–12–07; 8:45 am]
BILLING CODE 6820–61–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Meeting of the National Advisory
Council for Healthcare Research and
Quality
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of public meeting.
sroberts on PROD1PC70 with NOTICES
AGENCY:
SUMMARY: In accordance with section
10(a) of the Federal Advisory Committee
Act, this notice announces a meeting of
the National Advisory Council for
Healthcare Research and Quality.
DATES: The meeting will be held on
Friday, November 9, 2007, from 9 a.m.
to 3 p.m.
ADDRESSES: The meeting will be held at
the Eisenberg Conference Center,
Agency for Healthcare Research and
Quality, 540 Gaither Road, Rockville,
Maryland 20850.
FOR FURTHER INFORMATION CONTACT:
Deborah Queenan, Coordinator of the
Advisory Council, at the Agency for
Healthcare Research and Quality, 540
Gaither Road, Rockville, Maryland
20850, (301) 427–1330. For press-related
VerDate Aug<31>2005
21:55 Oct 12, 2007
Jkt 214001
information, please contact Karen
Migdail at (301) 427–1855.
If sign language interpretation or other
reasonable accommodation for a
disability is needed, please contact Mr.
Donald L. Inniss, Director, Office of
Equal Employment Opportunity
Program, Program Support Center, on
(301) 443–1144, no later than November
2, 2007. The agenda, roster, and minutes
are available from Ms. Bonnie Campbell,
Committee Management Officer, Agency
for Healthcare Research and Quality,
540 Gaither Road, Rockville, Maryland
20850. Her phone number is (301) 427–
1554.
SUPPLEMENTARY INFORMATION:
I. Purpose
The National Advisory Council for
Healthcare Research and Quality was
established in accordance with Section
921 (now Section 931) of the Public
Health Service Act (42 U.S.C. 299c). In
accordance with its statutory mandate,
the Council is to advise the Secretary of
the Department of Health and Human
Services and the Director, Agency for
Healthcare Research and Quality
(AHRQ), on matters related to actions of
the Agency to enhance the quality,
improve the outcomes, reduce the costs
of health care services, improve access
to such services through scientific
research, and to promote improvements
in clinical practice and in the
organization, financing, and delivery of
health care services. The Council is
composed of members of the public,
appointed by the Secretary, and Federal
ex-officio members.
II. Agenda
On Friday, November 9, the Council
meeting will convene at 9 a.m., with the
call to order by the Council Chair and
approval of previous Council minutes.
The Director, AHRQ, will present her
update on AHRQ’s current research,
programs, and initiatives. The agenda
will include a discussion of the National
Healthcare Quality and Disparities
Reports, needed research on Health Care
Value and Capacity Building. The
official agenda will be available on
AHRQ’s Web site at https://
www.ahrq.gov no later than November
2, 2007.
Dated: October 5, 2007.
Carolyn M. Clancy,
Director.
[FR Doc. 07–5057 Filed 10–12–07; 8:45 am]
BILLING CODE 4160–90–M
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
58309
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0098]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Focus Groups as
Used by the Food and Drug
Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
14, 2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0497. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Focus Groups as Used by the Food and
Drug Administration—(OMB Control
Number 0910–0497)—Extension
Focus groups provide an important
role in gathering information because
they allow for a more in-depth
understanding of consumers’ attitudes,
beliefs, motivations, and feelings than
do quantitative studies. Focus groups
serve the narrowly defined need for
direct and informal opinion on a
specific topic and as a qualitative
research toolhave three major purposes:
• To obtain consumer information
that is useful for developing variables
and measures for quantitative studies,
E:\FR\FM\15OCN1.SGM
15OCN1
Agencies
[Federal Register Volume 72, Number 198 (Monday, October 15, 2007)]
[Notices]
[Pages 58308-58309]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-20255]
=======================================================================
-----------------------------------------------------------------------
GENERAL SERVICES ADMINISTRATION
[OMB Control No. 3090-0250]
General Services Administration Acquisition Regulation;
Information Collection; Zero Burden Information Collection Reports
AGENCY: Office of the Chief Acquisition Officer, GSA.
ACTION: Notice of request for comments regarding a renewal to an
existing OMB clearance.
-----------------------------------------------------------------------
SUMMARY: Under the provisions of the Paperwork Reduction Act of 1995
(44 U.S.C. Chapter 35), the General Services Administration will be
submitting to the Office of Management and Budget (OMB) a request to
review and approve an extension of a currently approved information
collection requirement regarding zero burden information collection
reports. The clearance currently expires on August 31, 2007.
Public comments are particularly invited on: Whether this
collection of information is necessary and whether it will have
practical utility; whether our estimate of the public burden of this
collection of information is accurate and based on valid assumptions
and methodology; and ways to enhance the quality, utility, and clarity
of the information to be collected.
DATES: Submit comments on or before: December 14, 2007.
FOR FURTHER INFORMATION CONTACT: William Clark, Procurement Analyst,
Contract Policy Division, at telephone (202) 219-1813 or via e-mail to
william.clark @gsa.gov.
ADDRESSES: Submit comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for
reducing this burden to the Regulatory Secretariat (VIR), General
Services Administration, Room 4035, 1800 F Street, NW., Washington, DC
20405. Please cite OMB Control No. 3090-0250, Zero Burden Information
Collection Reports, in all correspondence.
SUPPLEMENTARY INFORMATION:
A. Purpose
This information requirement consists of reports that do not impose
collection burdens upon the public. These collections require
information which is already available to the public at large or that
is routinely exchanged by firms during the normal course of business. A
general control number for these collections decreases the amount of
paperwork generated by the approval process.
[[Page 58309]]
GSA has published rules in the Federal Register that fall under
information collection 3090-0250. The rule that prescribed clause
552.238-70 ``Identification of Electronic Office Equipment Providing
Accessibility for the Handicapped'' was published at 56 FR 29442, June
27, 1991, titled ``Implementation of Public Law 99-506'', with an
effective date of July 8, 1991; and Clause 552.238-74 ``Industrial
Funding Fee and Sales Reporting'' published at 68 FR 41286, July 11,
2003.
B. Annual Reporting Burden
None.
OBTAINING COPIES OF PROPOSALS: Requesters may obtain a copy of the
information collection documents from the General Services
Administration, Regulatory Secretariat (VIR), 1800 F Street, NW., Room
4035, Washington, DC 20405, telephone (202) 501-4755. Please cite OMB
Control No. 3090-0250, Zero Burden Information Collection Reports, in
all correspondence.
Dated: October 5, 2007.
Al Matera,
Director, Office of Acquisition Policy.
[FR Doc. E7-20255 Filed 10-12-07; 8:45 am]
BILLING CODE 6820-61-S